The use of subcutaneous erythropoietin and intravenous iron for the treatment of the anemia of severe, resistant congestive heart failure improves cardiac and renal function and functional cardiac class, and markedly reduces hospitalizations
Top Cited Papers
- 26 May 2000
- journal article
- Published by Elsevier BV in Journal of the American College of Cardiology
- Vol. 35 (7), 1737-1744
- https://doi.org/10.1016/s0735-1097(00)00613-6
Abstract
No abstract availableKeywords
This publication has 50 references indexed in Scilit:
- NKF-DOQI clinical practice guidelines for peritoneal dialysis adequacyAmerican Journal of Kidney Diseases, 1997
- Renal Anaemia Treatment with Recombinant Human Erythropoietin Increases Cardiac Output in Patients with Ischaemic Heart DiseaseScandinavian Journal of Urology and Nephrology, 1996
- A Multidisciplinary Intervention to Prevent the Readmission of Elderly Patients with Congestive Heart FailureNew England Journal of Medicine, 1995
- Blood levels of erythropoietin in congestive heart failure and correlation with clinical, hemodynamic, and hormonal profilesThe American Journal of Cardiology, 1994
- Pathogenesis of oedema in chronic severe anaemia: studies of body water and sodium, renal function, haemodynamic variables, and plasma hormones.Heart, 1993
- Changes in left ventricular size, wall thickness, and function in anemic patients treated with recombinant human erythropoietinAmerican Heart Journal, 1992
- The Erythrocyte Sedimentation Rate in Congestive Heart FailureNew England Journal of Medicine, 1991
- Therapy with Recombinant Human Erythropoietin Reduces Cardiac Size and Improves Heart Function in Chronic Hemodialysis PatientsAmerican Journal of Nephrology, 1991
- Precipitating Factors Leading to Decompensation of Heart FailureArchives of Internal Medicine, 1988
- Multivariate analysis using a linear discriminant function for predicting the prognosis of congestive heart failure.Japanese Circulation Journal, 1982